FarmaKology Newsletter - Issue #34
30 Drugs Facing Patent Expirations and Generic Entry in 2020 - 2021
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
JUXTAPID
Generic name: lomitapide mesylate
Patent Expiration / Generic Entry Opportunity February 21, 2020
Generic Entry Controlled by: Patent 5,712,279
JUXTAPID is a drug marketed by Aegerion. There are nine patents protecting this drug.
Learn more from here
APTIVUS
Generic name: tipranavir
Patent Expiration / Generic Entry Opportunity April 29, 2020
Generic Entry Controlled by: Patent 5,852,195
APTIVUS is a drug marketed by Boehringer Ingelheim. There are three patents protecting this drug.
Learn more from here
FORTOVASE
Generic name: saquinavir
Patent Expiration / Generic Entry Opportunity May 16, 2020
Generic Entry Controlled by: Patent 6,352,717
FORTOVASE is a drug marketed by Hoffmann La Roche. There is one patent protecting this drug.
Learn more from here
EGRIFTA
Generic name: tesamorelin acetate
Patent Expiration / Generic Entry Opportunity May 26, 2020
Generic Entry Controlled by: Patent 5,861,379
EGRIFTA is a drug marketed by Theratechnologies. There are five patents protecting this drug.
Learn more from here
VYXEOS
Generic name: cytarabine; daunorubicin
Patent Expiration / Generic Entry Opportunity August 03, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity
VYXEOS is a drug marketed by Celator Pharms. There are eight patents protecting this drug.
Learn more from here
CIPRODEX
Generic name: ciprofloxacin; dexamethasone
Patent Expiration / Generic Entry Opportunity August 10, 2020
Generic Entry Controlled by: Patent 6,359,016
CIPRODEX is a drug marketed by Novartis. There are six patents protecting this drug and one Paragraph IV challenge.
Learn more from here
SOLAGE
Generic name: mequinol; tretinoin
Patent Expiration / Generic Entry Opportunity August 24, 2020
Generic Entry Controlled by: Patent 5,194,247
SOLAGE is a drug marketed by Almirall. There is one patent protecting this drug.
Learn more from here
THALOMID
Generic name: thalidomide
Patent Expiration / Generic Entry Opportunity October 23, 2020
Generic Entry Controlled by: Patent 6,315,720
THALOMID is a drug marketed by Celgene. There are nine patents protecting this drug and three Paragraph IV challenges.
Learn more from here
DULERA
Generic name: formoterol fumarate; mometasone furoate
Patent Expiration / Generic Entry Opportunity December 20, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity
DULERA is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.
Learn more from here
OVIDREL
Generic name: choriogonadotropin alfa
Patent Expiration / Generic Entry Opportunity March 16, 2021
Generic Entry Controlled by: Patent 4,840,896
OVIDREL is a drug marketed by Emd Serono. There is one patent protecting this drug.
Learn more from here
DrugPatentWatch
DrugPatentWatch provides actionable business intelligence on small-molecule drugs
DrugPatentWatch serves leading companies ranging from biopharmaceutical R&D to healthcare delivery, and has been cited by CNN, NEJM, Nature Journals, and many other leading publications.
Use cases for the DrugPatentWatch platform include:
Branded pharmaceutical global business intelligence and forecasting
Generic drug and API manufacturer portfolio management
Wholesalers preventing overstock of off-patent drugs
Healthcare payer formulary management and budget management
Different plans are available, focusing on general business intelligence, expired patents, and forecasting.
